On the basis of these results, we hypothesized that coinhibition of p300/CBP and FLT3 may have therapeutic value in FLT3-ITD AML through targeting both epigenetic mechanisms and receptor tyrosine kinase signaling. The gene discussed is FLT3; the disease is acute myeloid leukemia.